Ad
related to: epstein-barr virus
Search results
Cancer: How the Epstein-Barr virus causes cancer cells to grow
Weston Forum· 3 days agoFIt’s a mystery to doctors in Singapore: nowhere in the world are so-called nasopharyngeal...
What Is a T-Cell Lymphoproliferative Disorder? Inside Halsey's Diagnosis
Health.com· 3 days agoHalsey, 29, was diagnosed and treated for both lupus and a rare white blood cell disorder, according...
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
MedPage Today· 3 days agoMolecular, genetic, and cellular analyses showed the two lymphomas had distinct immunophenotypes and...
Middle-Age Man Presents With Necrotizing Mass on Nose
MedPage Today· 5 days agoThe patient came to the hospital after developing a high fever and nose bleed, and said that the...
Healthy diet, once-weekly fatty fish intake may help keep MS at bay
MedicalNewsToday via AOL· 1 day agoA recent study has found a link between following a healthy, Mediterranean-type diet, and a lower...
Why Moderna Stock Is a No-Brainer Buy Right Now
Motley Fool via Yahoo Finance· 4 days agoBased on phase 2 data, the partners could seek accelerated approval of the combo as an adjuvant therapy for melanoma. Moderna also expects to soon...
Freestyle BMX Riders To Watch Ahead Of Paris 2024 Olympics: Nikita Ducarroz
Forbes· 3 days agoAt 27 years old, Nikita Ducarroz is one of the standard-bearers in women’s BMX freestyle. Competing...
Three Valley Bioscience Firms Reach FDA Milestones
Los Angeles Business Journal· 5 days agoThree San Fernando Valley companies in late May reached milestones with the Food and Drug Administration for their drugs and medical devices.
Young, women more likely to suffer from multiple sclerosis: Experts
Investing.com· 7 days agoNew Delhi, June 8 (IANS) Young adults and women are more likely to suffer from multiple sclerosis,...
Oppenheimer Increases Moderna (NASDAQ:MRNA) Price Target to $179.00
ETF DAILY NEWS· 16 hours agoModerna (NASDAQ:MRNA – Get Free Report) had its target price hoisted by analysts at Oppenheimer from $163.00 to $179.00 in a research report issued to clients and investors on Wednesday, Benzinga ...
